There can't be discussions with a BP when they are still doing due diligence with multiples.

"OK, another question is have we had to slow or stop any programs. And the answer is yes. Those programs that are involving large clinical trials have slowed. We haven’t stopped any programs, but there are things we would probably be doing more of if COVID wasn’t around, because the partnering and everything else would be complete. But with that dragging a little bit with COVID – that’s alright. We’ve got plenty to do as I mentioned, in writing publications, doing partnering due diligence – that is actually a lot of work, especially when you’re doing multiples." (bolding added)

Don't shoot the messenger ... Koo